NewsBenzingaChardan Capital维持对4D Molecular Therapeutics的买入评级，将目标价下调至25美元 Chardan Capital维持对4D Molecular Therapeutics的买入评级，将目标价下调至25美元 Benzinga 2026.10.06 12:26 (GMT+0) Open on Benzinga Other news TD Cowen Maintains Buy on Capital One Financial, Lowers Price Target to $242 Lamb Weston Beats Q1 Expectations, Raises 2027 Outlook As Cost-Saving Efforts Gain Traction Raymond James Downgrades Wesbanco to Market Perform TD Cowen Maintains Hold on Credit Acceptance, Lowers Price Target to $590 TD Cowen Maintains Hold on Bread Financial Holdings, Lowers Price Target to $111 Raymond James Downgrades Hilltop Hldgs to Underperform
